NCT06623110View on ClinicalTrials.gov

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2029

Conditions
High-Risk Oral Precancerous Disease
Interventions
BIOLOGICAL

RP2 Injection

Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.

Trial Locations (2)

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Replimune Inc.

INDUSTRY

lead

Glenn J. Hanna

OTHER